XNAS
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
BlossomHill’s key catalyst was updated Phase 1/2 SOLARA data for BH-30643 in EGFR-resistant NSCLC, which keeps the oncology story alive. But the quarter was ugly, with **EPS of -$8.75** versus **-$0.77** expected, a much deeper loss than hoped.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-18 | Q2 2026 | -0.77 | -8.75 | -1036.36% | $0 | ❌ Miss | -0.07% | — | — |
Showing last 1 quarters.